Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.
M30 antigen
M65 antigen
biomarkers
cell death
cytokeratin-18
hypertrophic cardiomyopathy
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
received:
10
07
2024
revised:
03
08
2024
accepted:
05
08
2024
medline:
28
8
2024
pubmed:
28
8
2024
entrez:
28
8
2024
Statut:
epublish
Résumé
Hypertrophic cardiomyopathy (HCM) is a heart muscle disease associated with an increased risk for sudden cardiac death (SCD). Cytokeratin 18-based proteins, such as M30 and M65 antigens, are known cell-death biomarkers. M30 antigen is released from cells during apoptosis, and M65 antigen is released during cell death from any cause, such as apoptosis or necrosis. We aimed to study the expression of M30 and M65 antigens in peripheral blood obtained by 46 HCM patients and compare with 27 age- and sex-matched patients without HCM. We also investigated the CK18 expression in myocardium from postmortem HCM hearts. M30 and M65 antigens were significantly increased in the HCM vs. non-HCM group (Μ30: 338 ± 197 U/uL vs. 206 ± 166 U/uL,
Identifiants
pubmed: 39195218
pii: cells13161328
doi: 10.3390/cells13161328
pii:
doi:
Substances chimiques
Keratin-18
0
Biomarkers
0
M65 antigen, human
0
Peptide Fragments
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Hellenic Cardiological Society
ID : 17-07-2017